Advertisement
Advertisement
U.S. Markets open in 21 mins
Advertisement
Advertisement
Advertisement
Advertisement

Galmed Pharmaceuticals Ltd. (GLMD)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.4825-0.0076 (-1.55%)
At close: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.4901
Open0.5000
Bid0.4500 x 4000
Ask0.4921 x 3000
Day's Range0.4700 - 0.5000
52 Week Range0.4170 - 3.4200
Volume21,890
Avg. Volume96,462
Market Cap12.103M
Beta (5Y Monthly)1.95
PE Ratio (TTM)N/A
EPS (TTM)-1.4880
Earnings DateMar 16, 2022 - Mar 21, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.50
  • PR Newswire

    Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification

    Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic, fibrosis and inflammatory diseases today announced that the Company received a letter from the Nasdaq Listing Qualifications (the "Letter"), indicating that the Company is not in compliance with the minimum bid price requirement for continued listing set forth in Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00

  • Zacks

    Evotec (EVO) Inks Drug Discovery Collaboration Deal With J&J

    Evotec (EVO) signs a collaboration agreement with Janssen, a wholly owned subsidiary of J&J, for discovering novel drugs in the field of protein homeostasis. Shares down.

  • PR Newswire

    Galmed Pharmaceuticals Reports First Quarter 2022 Financial Results

    TEL AVIV, Israel, May 17, 2022 /PRNewswire/ —Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic, fibrosis and inflammatory diseases reports financial results for the three months ended March 31, 2022.

Advertisement
Advertisement